EyePoint Pharmaceuticals Inc Sustainability Reports

A clinical-stage biopharmaceutical company developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases using Durasert technology.

Sector: Manufacturing

Country: United States

Exchange: Nasdaq

LEI: 549300QE1RU34T50MR69

FIGI: BBG001SNLCD2

6 reports from 2018 to 2025

• EyePoint Pharmaceuticals Inc 2025 Environmental, Social, and Governance (ESG) Performance Report
• EyePoint Pharmaceuticals Inc 2024 Environmental, Social, and Governance (ESG) Performance Report
• EyePoint Pharmaceuticals Inc 2023 Environmental, Social and Governance (ESG) Performance Report
• EyePoint Pharmaceuticals Inc 2022 Environmental, Social and Governance (ESG) Performance Report
• EyePoint Pharmaceuticals Inc 2019 Form 10-K